MEDP Q1 Earnings Call: Outperformance Driven by Revenue Upside, Cautious Outlook Amid Funding Uncertainty

MEDP Cover Image
MEDP Q1 Earnings Call: Outperformance Driven by Revenue Upside, Cautious Outlook Amid Funding Uncertainty

In This Article:

Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance of $2.19 billion at the midpoint came in 2% above analysts’ estimates. Its GAAP profit of $3.67 per share was 20.8% above analysts’ consensus estimates.

Is now the time to buy MEDP? Find out in our full research report (it’s free).

Medpace (MEDP) Q1 CY2025 Highlights:

  • Revenue: $558.6 million vs analyst estimates of $527.1 million (9.3% year-on-year growth, 6% beat)

  • EPS (GAAP): $3.67 vs analyst estimates of $3.04 (20.8% beat)

  • Adjusted EBITDA: $118.6 million vs analyst estimates of $117.9 million (21.2% margin, 0.6% beat)

  • The company lifted its revenue guidance for the full year to $2.19 billion at the midpoint from $2.16 billion, a 1.4% increase

  • EPS (GAAP) guidance for the full year is $12.65 at the midpoint, beating analyst estimates by 2.9%

  • EBITDA guidance for the full year is $477 million at the midpoint, in line with analyst expectations

  • Operating Margin: 20.3%, in line with the same quarter last year

  • Free Cash Flow Margin: 20.7%, down from 28.8% in the same quarter last year

  • Organic Revenue rose 9.4% year on year (17.6% in the same quarter last year)

  • Market Capitalization: $8.51 billion

StockStory’s Take

Medpace’s first quarter results reflected higher-than-expected revenue, as management cited both improved program progression and a rise in reimbursable cost activity as key contributors. CEO August Troendle explained that while active clinical trial programs advanced well, some of the revenue upside was due to elevated investigator-related costs, with inflation and patient scarcity driving site expenses higher. The company also highlighted an uptick in pass-through costs as a factor in the revenue increase.

Looking ahead, management emphasized the importance of backlog conversion and the overall funding environment for small biopharma clients. Troendle outlined that while the company’s revenue guidance assumes stable cancellation rates and ongoing project execution, there remains risk from continued funding challenges among clients. CFO Kevin Brady reinforced that most of the year’s expected revenue is supported by existing backlog, but cautioned that higher-than-normal cancellations or delays could impact future growth.

Key Insights from Management’s Remarks

Medpace’s management focused on explaining the underlying trends affecting both quarterly results and the outlook for the business. They provided detail on competitive dynamics, funding headwinds, and backlog progression shaping the company’s fundamentals.